Loading...

ARCT ARCTURUS THERAPEUTICS HOLDINGS INC Product Launches 8-K Filing

RCTR

RCT

ARCTURUS THERAPEUTICS HOLDINGS INC

(ARCT)

2024 8-K

Financial Results Update

Interim Results Report

COVID-19 Vaccine Update

Vaccine Approval Update

Product Expansion

Financial Statements

Financial Results

Financial Results

Corporate Presentation

Financial Results and Corpo...

Appointment of Dr. Moncef S...

Annual Meeting of Stockholders

Earnings Report

Dismissal of Previous Indep...

COVID-19 Vaccine Success

Financial Update

Financial Results and Corpo...

Financial Results and Corpo...

Amendment Agreement with Cy...

Amendment to Collaboration ...

Financial Results and Corpo...

Annual Meeting of Stockholders

Financial Results and Corpo...

COVID-19 Vaccine Submission...

Credit Agreement with Wells...

Distribution Agreement

Financial Results and Corpo...

Termination of Loan Agreement

External Links:

Arcturus Therapeutics' COVID-19 vaccine candidate met the primary endpoint in a Phase III clinical study in Japan, according to a press release by Meiji Seika Pharma.

AI Assistant

ARCTURUS THERAPEUTICS HOLDINGS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.